Articles from AI Proteins

AI Proteins, a biotech company pioneering a new class of de novo therapeutic miniproteins designed by artificial intelligence, today announced the appointment of Dr. James Bowman, PhD as its first Chief Technology Officer. In this role, James will drive the expansion of the company’s core technology platform, integrating machine learning, synthetic biology, robotics, and large-scale data analysis to create entirely novel protein therapeutics. He previously served as AI Proteins’ Director of Protein Engineering, where he helped establish the framework that powers the company’s discovery engine.

AI Proteins, a Boston-based biotech company pioneering the design of novel miniprotein therapeutics, today announced that its President, CEO, and Founder, Chris Bahl, will be speaking on the main stage at the prestigious TED conference in Vancouver, Canada. His talk will focus on the company's groundbreaking work in designing and developing the next generation of miniprotein therapeutics to address a wide range of diseases.

AI Proteins (“AIP”), the biotechnology company bringing a novel approach to therapeutic development with its de novo protein design platform, today announced that Wendy Dwyer has joined the company as Chief Business Officer. In her role, Ms. Dwyer will help lead AIP in forming partnerships to demonstrate the power of its high-throughput miniprotein design platform in developing new pharmaceutical therapies.

AI Proteins, the biotechnology company using artificial intelligence to design synthetic proteins de novo, today announced its public launch and the close of an oversubscribed $18.2 million seed series co-led by Cobro Ventures and Lightchain Capital. AI Proteins has built the first high-throughput platform that can design entirely synthetic proteins from scratch (“de novo”), giving engineers an unprecedented amount of control over protein function and properties.